Ambryon Biosciences

Unlocking the signaling potential of GPI-anchored proteins through lipolytic cleavage

Borza et al. (2025). Trends Cell Biol·Citations: 8Review

Cell-intrinsic lipolytic release of GPI-anchored proteins was long elusive. This opinion article reviews the GPI-specific phospholipases GDE2, GDE3, GDE6 and PGAP6, stating that GDE2 cleaves as a PLD and GDE3 as a PLC, leaving phosphatidic acid or diacylglycerol on the surface.

Key findings

  • A GPI anchor attaches a protein to the plasma membrane's outer leaflet through a phosphatidylinositol lipid tail, a variable glycan core and a phosphoethanolamine linker; anchoring is irreversible, and about 30 mammalian genes are involved in GPI-anchored protein biosynthesis.

  • GDE2 releases RECK, GPC2, GPC3, GPC4, GPC6, CD59 and TFPI, whereas uPAR, TIKI, contactins and CD58 are released by GDE3 and resist GDE2; GDE3 is more promiscuous, but overexpression-based assays leave physiological relevance unestablished for several substrates.

  • GDE2 and GDE3 also hydrolyze soluble glycerophospholipid-like substrates. GDE2 hydrolyzes glycerol 3-phosphocholine (GPCho) to release choline and is resistant to glycerol 3-phosphoinositol (GroPIns) and lysophosphatidylinositol (LPI), whereas GDE3 hydrolyzes GroPIns and LPI and is resistant to GPCho.

  • GDE3 hydrolyzes lysophosphatidylinositol (LPI), a GPR55 agonist, in vitro and in vivo as a lyso-PI-PLC, limiting receptor-active LPI and producing the cannabinoid receptor agonist 2-arachidonoylglycerol (2-AG), thereby switching between GPR55 and cannabinoid receptor signaling.

  • GDE2 promotes neuroblastoma cell differentiation by releasing GPI-anchored glypican-6 (GPC6), driving neurite outgrowth, suppressing motility, resisting neurite retraction via the Rac/RhoA balance and upregulating differentiation genes; high GDPD5 expression correlates with favorable clinical outcome.

  • GDE2 sustains ADAM10 cleavage of APP in the brain by releasing RECK, yielding soluble APPalpha; Gde2 knockout mice show progressive neurodegeneration, synaptic dysfunction, increased amyloid beta deposition and memory deficits, with raised GPI-anchored RECK and suppressed ADAM10 activity.

  • GDE3 cleaves GPI-anchored urokinase plasminogen activator receptor (uPAR, PLAUR) to release soluble uPAR (suPAR) in breast cancer cells. By depleting uPAR from basolateral membrane domains, GDE3 suppresses the transformed phenotype of breast cancer cells in vitro and in vivo.

  • In oligodendrocyte precursor cells (OPCs), GDE3 cleaves GPI-anchored ciliary neurotrophic factor receptor alpha (CNTFRalpha) in a cell-autonomous manner. The soluble CNTFRalpha activates CNTF receptor signaling and prevents excessive OPC proliferation.

  • In human vascular endothelial cells (HUVECs), a large proportion of GDE2 is stored in Weibel-Palade bodies and traffics to the cell surface upon histamine stimulation. There GDE2 releases the GPI-anchored complement inhibitor CD59 and the anticoagulant TFPI.

  • Neuronal GDE2 undergoes clathrin-dependent endocytosis requiring C-terminal Leu553, then recycles via fast Rab4 and slow Rab11 routes; GDE2(delta560) prefers the fast route and is dysfunctional, whereas a further tail deletion retains GDE2 at the surface with gain of function.

  • GPI-anchored proteins lack a transmembrane domain and sit in lipid rafts; bacterial PI-PLC and endogenous GPI-specific phospholipases cleave them from the surface. The human proteome has more than 160 GPI-anchored proteins.

  • GDE2, GDE3 and GDE6 are six-transmembrane proteins with a TIM-barrel catalytic ectodomain, whereas PGAP6 is a seven-transmembrane GPI-PLA2 with catalytic residues inside its helices, acting as an intramembrane rather than interfacial enzyme.

  • GDE2 cleaves GPI anchors as a PLD, leaving phosphatidic acid (PA) exposed on the cell surface, while GDE3 acts as a PLC and leaves diacylglycerol (DAG); the surface-exposed signaling roles of PA and DAG are unexplored.

  • PGAP6 converts GPI-anchored CRIPTO to lysoGPI-anchored CRIPTO, which is spontaneously released; plasma GPI-PLD (GPLD1) then releases lysophosphatidic acid (LPA) from the soluble form, making CRIPTO lipid-free.

  • Soluble anchorless CRIPTO binds Nodal, a TGFbeta family member, to promote embryonic development, and Pgap6 knockout mice are embryonic lethal with phenotypes similar to Cripto knockout embryos. CRIPTO release is strongly induced by multiple growth factors and by LPA.

  • Human GDE6 is not a functional protein: a primate-specific single-base deletion in GDPD4 exon 3 truncates the N-terminus, preventing correct folding and localization, so human GDE6 accumulates in vesicles, whereas chicken GDE6 is functional at the cell surface.

Described parts & designs

Author abstract

Glycosylphosphatidylinositol (GPI)-anchored proteins (APs) regulate numerous biological processes through interaction with signaling effectors at the cell surface. As a unique feature, GPI-APs can be released from their anchors by multi-pass GPI-specific phospholipases (types A2, C, and D) to impact signaling networks, phenotype, and cell fate; however, many questions remain outstanding. Here, we discuss and expand our current understanding of the distinct GPI-specific phospholipases, their substrates, effector pathways, and emerging physiological roles, with a focus on the six-transmembrane ecto-phospholipases GDE2 (GDPD5) and GDE3 (GDPD2). We provide structural insight into their AlphaFold-predicted inner workings, revealing how transmembrane (TM) domain plasticity may enable GPI-anchor binding and hydrolysis. Understanding lipolytic cleavage of GPI-APs adds a new dimension to their signaling capabilities and biological functions.

Identifiers & revision